BioLineRx (BLRX) Closes BL-8040 In-License Agreement
Get Alerts BLRX Hot Sheet
Join SI Premium – FREE
On September 4, 2012, BioLineRx Ltd. (Nasdaq: BLRX) entered into an agreement (the “Agreement”) with Biokine Therapeutics Ltd. to in-license the rights to BL-8040 for the treatment of acute myeloid leukemia, as well as other types of hematological cancer. The closing of the transaction was subject to formal approval of the Office of the Chief Scientist of Israel’s Ministry of Industry, Trade and Labor (the “OCS”). The approval of the OCS was obtained on January 14, 2013, and therefore the transaction has now closed and the Agreement has become effective according to its terms.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seelos Therapeutics (SEEL) Provides Update on Top-Line Results from its ALS Study
- Hoth Therapeutics (HOTH) Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
- Alan Kirshner, former Chairman and CEO of Markel Group (MKL), passes away
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!